CoChat

Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis

Open access

The DOI matches its Crossref record; 57 of the 58 references it cites were found in a registry or an index.

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists are used to treat diabetes, but their effects on nonalcoholic steatohepatitis (NASH) and the development of hepatocellular carcinoma (HCC) remain unclear. In this study, mice with streptozotocin- and high-fat diet-induced diabetes and NASH were subcutaneously treated with liraglutide or saline (control) for 14 weeks. Glycemic control, hepatocarcinogenesis, and liver histology were compared between the groups. Fasting blood glucose levels were significantly lower in the liraglutide group than in the control group (210.0 ± 17.3 mg/dL vs. 601.8 ± 123.6 mg/dL), and fasting insulin levels were significantly increased by liraglutide (0.18 ± 0.06 ng/mL vs. 0.09 ± 0.03 ng/mL). Liraglutide completely suppressed hepatocarcinogenesis, whereas HCC was observed in all control mice (average tumor count, 5.5 ± 3.87; average tumor size, 8.1 ± 5.0 mm). Liraglutide significantly ameliorated steatosis, inflammation, and hepatocyte ballooning of non-tumorous lesions in the liver compared with the control findings, and insulin-positive β-cells were observed in the pancreas in liraglutide-treated mice but not in control mice. In conclusion, liraglutide ameliorated NASH and suppressed hepatocarcinogenesis in diabetic mice. GLP-1 receptor agonists can be used to improve the hepatic outcome of diabetes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21165722

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effect of liraglutide on body weight and biochemical variables. Mice were euthanatized at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) weeks (w) of age. Changes in body weight (A), blood glucose (B), insulin (C), and alanine aminotransferase (ALT). Duration of the treatment periods are shown as line graphs (D). Data are presented as the mean, and error bars represent the standard deviation. Triangle: liraglutide (LIRA)-treated mice; square: control mice (CTR). * p < 0.05 and ** p < 0.01 vs. CTR.
Figure 1 Effect of liraglutide on body weight and biochemical variables. Mice were euthanatized at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) weeks (w) of age. Changes in body weight (A), blood glucose (B), insulin (C), and alanine aminotransferase (ALT). Duration of the treatment periods are shown as line graphs (D). Data are presented as the mean, and error bars represent the standard deviation. Triangle: liraglutide (LIRA)-treated mice; square: control mice (CTR). * p < 0.05 and ** p < 0.01 vs. CTR.CC BY · PubMed Central
Figure 2 Effect of liraglutide on hepatocarcinogenesis. Representative contrast-enhanced computed tomography images of control mice (CTR) (A) and liraglutide-treated mice (LIRA) (B). # and dotted line circles denote the HCC lesions. Macroscopic image of the liver surface (CTR (C); LIRA (D)). Histological images with hematoxylin and eosin staining in the CTR (E) and LIRA groups (F). Anti-glutamine synthetase staining of CTR (CTR (G); LIRA (H)). Total number of tumor lesions (I) and maximum size (J) of tumors in the liver were compared between the groups (n = 6/group). All images and histological samples were obtained from mice at 20 weeks of age. * p < 0.05 and ** p < 0.01 vs. CTR.
Figure 2 Effect of liraglutide on hepatocarcinogenesis. Representative contrast-enhanced computed tomography images of control mice (CTR) (A) and liraglutide-treated mice (LIRA) (B). # and dotted line circles denote the HCC lesions. Macroscopic image of the liver surface (CTR (C); LIRA (D)). Histological images with hematoxylin and eosin staining in the CTR (E) and LIRA groups (F). Anti-glutamine synthetase staining of CTR (CTR (G); LIRA (H)). Total number of tumor lesions (I) and maximum size (J) of tumors in the liver were compared between the groups (n = 6/group). All images and histological samples were obtained from mice at 20 weeks of age. * p < 0.05 and ** p < 0.01 vs. CTR.CC BY · PubMed Central
Figure 3 Representative histological images of non-tumorous lesions at 20 weeks (w) of age. Hematoxylin and eosin(A–E), staining (HE). Oil red O staining (F–J). Sirius red staining (K–O). LIRA: liraglutide-treated mice; CTR: control mice
Figure 3 Representative histological images of non-tumorous lesions at 20 weeks (w) of age. Hematoxylin and eosin(A–E), staining (HE). Oil red O staining (F–J). Sirius red staining (K–O). LIRA: liraglutide-treated mice; CTR: control miceCC BY · PubMed Central
Figure 4 Histological evaluation of non-tumorous lesions. Mice were euthanatized at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) weeks (w) of age. Changes in total nonalcoholic fatty liver disease activity score (NAS) (A), steatosis score (B), inflammation score (C), ballooning score (D), fat deposition areas evaluated using oil red O-stained samples (E), and fibrotic areas evaluated using Sirius red-stained samples (F) are presented as line graphs. Data are presented as the mean, and error bars represent the standard deviation. Triangle: liraglutide-treated mice (LIRA); square: control mice (CTR). * p < 0.05 and ** p < 0.01 vs. CTR.
Figure 4 Histological evaluation of non-tumorous lesions. Mice were euthanatized at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) weeks (w) of age. Changes in total nonalcoholic fatty liver disease activity score (NAS) (A), steatosis score (B), inflammation score (C), ballooning score (D), fat deposition areas evaluated using oil red O-stained samples (E), and fibrotic areas evaluated using Sirius red-stained samples (F) are presented as line graphs. Data are presented as the mean, and error bars represent the standard deviation. Triangle: liraglutide-treated mice (LIRA); square: control mice (CTR). * p < 0.05 and ** p < 0.01 vs. CTR.CC BY · PubMed Central
Figure 5 Histological images of the pancreas. Mice were euthanatized at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) weeks (w) of age. There were no anti-insulin antibody-stained cells at baseline (A), 12 w (B), and 20 w (C) in the control mice (CTR), whereas islets with insulin-positive (Ins+) cells were observed in the liraglutide-treated mice (LIRA) (D,E). The counts of Ins + cells (F) and islets with Ins+ cells (G) were compared between the groups. Data are presented as the mean, and error bars represent the standard deviation. Triangle: LIRA (n = 4–6); square: CTR (n = 4–6). * p < 0.05 and ** p < 0.01 vs. CTR.
Figure 5 Histological images of the pancreas. Mice were euthanatized at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) weeks (w) of age. There were no anti-insulin antibody-stained cells at baseline (A), 12 w (B), and 20 w (C) in the control mice (CTR), whereas islets with insulin-positive (Ins+) cells were observed in the liraglutide-treated mice (LIRA) (D,E). The counts of Ins + cells (F) and islets with Ins+ cells (G) were compared between the groups. Data are presented as the mean, and error bars represent the standard deviation. Triangle: LIRA (n = 4–6); square: CTR (n = 4–6). * p < 0.05 and ** p < 0.01 vs. CTR.CC BY · PubMed Central
Figure 6 Effect of delayed treatment with liraglutide on hepatocarcinogenesis. (A) Experimental design and protocol. A total of 200 µg streptozotocin was injected into 15-day-old male mice at 2 days after birth followed by feeding with a high-fat diet after 4 weeks (w) of age. Mice were killed at 20 w of age (n = 6/group). Mice were treated with liraglutide (LIRA) or saline (CTR) for 11 w starting at 9 w of age and were killed at 20 w of age. (B) Macroscopic image of the liver surface. The total number of tumor lesions (C) and maximum size (D) of tumors in the liver were compared between the groups. CTR: control mice; LIRA: liraglutide-treated mice; STZ: streptozotocin; SC: subcutaneous injection; HFD: high-fat diet.
Figure 6 Effect of delayed treatment with liraglutide on hepatocarcinogenesis. (A) Experimental design and protocol. A total of 200 µg streptozotocin was injected into 15-day-old male mice at 2 days after birth followed by feeding with a high-fat diet after 4 weeks (w) of age. Mice were killed at 20 w of age (n = 6/group). Mice were treated with liraglutide (LIRA) or saline (CTR) for 11 w starting at 9 w of age and were killed at 20 w of age. (B) Macroscopic image of the liver surface. The total number of tumor lesions (C) and maximum size (D) of tumors in the liver were compared between the groups. CTR: control mice; LIRA: liraglutide-treated mice; STZ: streptozotocin; SC: subcutaneous injection; HFD: high-fat diet.CC BY · PubMed Central
Figure 7 Experimental design and protocol. A total of 200 µg streptozotocin was injected into 15-day-old male mice at 2 days after birth followed by feeding with a high-fat diet after 4 weeks (w) of age. Mice were killed at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) w of age. Mice were treated with liraglutide or saline for 6 w or 14 w until death. CTR: control mice; LIRA: liraglutide-treated (0.15 mg/kg by subcutaneous injection) mice; STZ: streptozotocin; SC: subcutaneous injection; HFD: high-fat diet.
Figure 7 Experimental design and protocol. A total of 200 µg streptozotocin was injected into 15-day-old male mice at 2 days after birth followed by feeding with a high-fat diet after 4 weeks (w) of age. Mice were killed at 6 (n = 4 for baseline), 12 (n = 6/group), and 20 (n = 6/group) w of age. Mice were treated with liraglutide or saline for 6 w or 14 w until death. CTR: control mice; LIRA: liraglutide-treated (0.15 mg/kg by subcutaneous injection) mice; STZ: streptozotocin; SC: subcutaneous injection; HFD: high-fat diet.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 57 references

Cited by

See all 74

Metadata

Authors
Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., & Anzai, K.
Affiliations
  • Saga University (JP)
  • Kyushu University (JP)
  • Kurume University (JP)
Corresponding author
Anzai, Keizo
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-08-10
Volume
21
Issue
16
Pages
5722
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3047956076
Cited by
69
References
58
Citations by year
2026: 13 · 2025: 17 · 2024: 14 · 2023: 12 · 2022: 10 · 2021: 3
FWCI
4.48
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Keywords
GLP-1 receptor agonists, liraglutide, nonalcoholic steatohepatitis, hepatocellular carcinoma, hepatocarcinogenesis, diabetes mellitus, streptozotocin-induced diabetes, high-fat diet, hepatic steatosis, liver inflammation, hepatocyte ballooning, insulin, pancreatic beta cells, glycemic control
MeSH terms
Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Blood Glucose, Diabetes Mellitus, Experimental, Disease Models, Animal, Carcinoma, Hepatocellular, Hypoglycemic Agents, Insulin, Liver Neoplasms, Male, Mice, Inbred C57BL, Streptozocin, Treatment Outcome, Mice, Diet, High-Fat, Carcinogenesis, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. https://app.cochat.ai/papers/10.3390/ijms21165722
The paper
Kojima, M., Takahashi, H., Kuwashiro, T., Tanaka, K., Mori, H., Ozaki, I., Kitajima, Y., Matsuda, Y., Ashida, K., Eguchi, Y., & Anzai, K. (2020). Glucagon-Like Peptide-1 Receptor Agonist Prevented the Progression of Hepatocellular Carcinoma in a Mouse Model of Nonalcoholic Steatohepatitis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21165722

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.